Identification
- Generic Name
- Inbakicept
- DrugBank Accession Number
- DB16479
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Inbakicept
- External IDs
- ALT-803
- ALT803
- N-803
- WHO 1102
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Inbakicept is a human IL-15 superagonist with immunostimulatory properties. Though a promising anti-cancer biologic, the drug is also being investigated as an HIV cure. It has the ability to reactivate latent virus, and has the potential to enhance anti-viral immune repsonses in these chronic infections.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- QN4LI58PJ5
- CAS number
- 2135939-52-3
References
- General References
- Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB: The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. doi: 10.1371/journal.ppat.1008339. eCollection 2020 Mar. [Article]
- McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, Silvestri G: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Active Not Recruiting Treatment Cervical Cancer / Colorectal Cancer / Gastric Cancer / Hepatocellular Carcinoma / Melanoma / Merkel Cell Carcinoma / Microsatellite Instability / Mismatch Repair Deficient (dMMR) / Non-Small Cell Lung Cancer (NSCLC) / Renal Cell Carcinoma (RCC) / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Urothelial Carcinoma 1 2 Active Not Recruiting Treatment Colorectal Cancer / Small Intestine Cancer 1 2 Active Not Recruiting Treatment Pancreatic Cancer 1 2 Completed Treatment Acute Myeloid Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:47 / Updated at September 15, 2021 23:26